Blood Tests for Alzheimer's: How Plasma Biomarkers Are Changing Early Detection

For decades, confirming Alzheimer's pathology required either a lumbar puncture (spinal tap) to measure amyloid and tau in cerebrospinal fluid, or an amyloid PET scan — both expensive, specialist-administered, and inaccessible to most people who might benefit from early diagnosis. Blood-based biomarkers represent a fundamentally different approach: detecting the molecular signatures of Alzheimer's pathology in a simple blood draw.

The key biomarkers being developed include phosphorylated tau-217 (p-tau217), phosphorylated tau-181 (p-tau181), amyloid-beta 42/40 ratio, glial fibrillary acidic protein (GFAP), and neurofilament light chain (NfL). Each reflects a different aspect of Alzheimer's pathology: tau abnormalities, amyloid accumulation, neuroinflammation, or neuronal damage.

The most validated and commercially available platforms include Lumipulse (Fujirebio), Quanterix Simoa HD-X, and the ALZpath p-tau217 assay. These platforms differ in analytical sensitivity and the specific biomarkers they measure, but the leading candidates — particularly p-tau217 — have demonstrated striking diagnostic accuracy in multiple independent cohorts.

A landmark study published in JAMA in 2024 evaluated the ALZpath p-tau217 assay in a primary care cohort and found it achieved approximately 90% sensitivity and specificity for detecting amyloid positivity confirmed by PET — comparable to cerebrospinal fluid testing and substantially better than clinical diagnosis alone. This study was notable because the cohort included patients seen in primary care settings, not specialist memory clinics, demonstrating potential real-world applicability.

Plasma p-tau217 in particular has emerged as the leading candidate. Multiple independent validation studies have shown that elevated p-tau217 is strongly predictive of amyloid pathology and tracks the transition from preclinical to clinical Alzheimer's earlier than other biomarkers. A large European study published in Nature Medicine in 2023 demonstrated that p-tau217 could predict Alzheimer's pathology with high accuracy up to a decade before symptom onset.

The FDA cleared Lumipulse plasma amyloid and tau tests in 2024 for use as part of Alzheimer's diagnosis evaluation, marking an important regulatory milestone. Several other platforms are in late-stage validation. The field is moving toward standardization of cutoffs and validation across diverse populations, which remains an important ongoing challenge.

Blood tests do not replace clinical evaluation and cognitive assessment — they are a tool within a diagnostic workup. A positive result requires clinical interpretation in the context of symptoms, cognitive testing, and often confirmatory imaging or CSF testing before treatment decisions are made.

For people with cognitive concerns, blood-based biomarkers represent a potential path to earlier, more accessible diagnostic clarity. Instead of waiting months or years for a specialist PET scan, a blood draw at a primary care appointment could provide initial biomarker information that either reassures or escalates the evaluation.

It is important to understand what a blood test can and cannot tell you. A positive p-tau217 test indicates the presence of Alzheimer's-related pathology in the brain — but it does not tell you what stage the disease is at, how quickly symptoms will progress, or whether you will develop clinical symptoms on any particular timeline. Biomarker positivity can precede symptoms by many years.

If you are considering asking your doctor about a blood-based Alzheimer's test, it is worth having a clear conversation about what you would want to do with the results. A positive result may be actionable if you are symptomatic and evaluating treatment eligibility. In someone without symptoms, a positive result enters more complex territory around disclosure, monitoring, and the psychological implications of knowing.

These tests are most useful currently in people with memory concerns who are being evaluated for possible MCI or early Alzheimer's — not as general population screening. The context of clinical symptoms is essential for interpretation.

The development of reliable blood-based biomarkers has the potential to fundamentally change who can access early Alzheimer's diagnosis. PET scanning costs $3,000 to $6,000 and is available only at specialist centers. A blood test costing $200 to $400 that can be ordered by a primary care physician changes the scale of who can be evaluated and who can be identified early enough to benefit from emerging treatments.

This matters enormously given the emergence of anti-amyloid therapies like lecanemab and donanemab. These drugs require confirmed amyloid pathology before treatment can begin. If that confirmation can happen via a blood draw rather than a PET scan, the bottleneck in treatment access shifts substantially. Blood tests could transform early Alzheimer's treatment from a specialist-only intervention to something accessible in the primary care system.

For clinical trial recruitment, blood tests are already transforming the landscape. Recruiting for trials previously required extensive PET screening. Blood tests allow much more efficient identification of eligible participants, potentially accelerating the pace of trial completion and drug development.

Looking further ahead, the convergence of blood biomarkers, digital cognitive monitoring, and genetic risk profiling is moving toward a future where Alzheimer's risk stratification and monitoring could be integrated into routine preventive care — much as cardiovascular risk is monitored through blood cholesterol and pressure.